243 related articles for article (PubMed ID: 34331819)
1. Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature.
Ottevanger R; van Beugen S; Evers AWM; Willemze R; Vermeer MH; Quint KD
J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2377-2387. PubMed ID: 34331819
[TBL] [Abstract][Full Text] [Related]
2. Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument.
McCaffrey S; Black RA; Nagao M; Sepassi M; Sharma G; Thornton S; Kim YH; Braverman J
J Med Internet Res; 2019 Jan; 21(1):e11302. PubMed ID: 30617041
[TBL] [Abstract][Full Text] [Related]
3. Clinical severity measures and quality-of-life burden in patients with mycosis fungoides and Sézary syndrome: comparison of generic and dermatology-specific instruments.
Herbosa CM; Semenov YR; Rosenberg AR; Mehta-Shah N; Musiek AC
J Eur Acad Dermatol Venereol; 2020 May; 34(5):995-1003. PubMed ID: 31630443
[TBL] [Abstract][Full Text] [Related]
4. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
Molloy K; Jonak C; Woei-A-Jin FJSH; Guenova E; Busschots AM; Bervoets A; Hauben E; Knobler R; Porkert S; Fassnacht C; Cowan R; Papadavid E; Beylot-Barry M; Berti E; Alberti Violetti S; Estrach T; Matin R; Akilov O; Vakeva L; Prince M; Bates A; Bayne M; Wachsmuch R; Wehkamp U; Marschalko M; Servitje O; Turner D; Weatherhead S; Wobser M; Sanches JA; McKay P; Klemke D; Peng C; Howles A; Yoo J; Evison F; Scarisbrick J
Br J Dermatol; 2020 Mar; 182(3):770-779. PubMed ID: 31049926
[TBL] [Abstract][Full Text] [Related]
5. Mycosis fungoides and Sézary syndrome.
Jonak C; Tittes J; Brunner PM; Guenova E
J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
[TBL] [Abstract][Full Text] [Related]
6. Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator.
Ottevanger R; van Beugen S; Evers AWM; Willemze R; Vermeer MH; Quint KD
JAAD Int; 2022 Dec; 9():57-64. PubMed ID: 36147217
[TBL] [Abstract][Full Text] [Related]
7. An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma.
Hu M; Scheffel J; Elieh-Ali-Komi D; Maurer M; Hawro T; Metz M
Clin Exp Med; 2023 Dec; 23(8):4177-4197. PubMed ID: 37555911
[TBL] [Abstract][Full Text] [Related]
8. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
9. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and severity of pruritus in cutaneous T cell lymphoma.
Vij A; Duvic M
Int J Dermatol; 2012 Aug; 51(8):930-4. PubMed ID: 22788808
[TBL] [Abstract][Full Text] [Related]
11. Lifestyle, demographic and Skindex measures associated with cutaneous T-cell lymphoma: a single institution cohort study.
Nguyen M; LeWitt T; Pang Y; Bagnowski K; Espinosa ML; Choi J; Guitart J; Liszewski W; Zhou XA
Arch Dermatol Res; 2023 Mar; 315(2):275-278. PubMed ID: 35668201
[TBL] [Abstract][Full Text] [Related]
12. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
[TBL] [Abstract][Full Text] [Related]
13. Mapping signal transducer and activator of transcription (STAT) activity in different stages of mycosis fungoides and Sezary syndrome.
Olszewska B; Żawrocki A; Lakomy J; Karczewska J; Gleń J; Zabłotna M; Malek M; Jankau J; Lange M; Biernat W; Nowicki RJ; Sokołowska-Wojdyło M
Int J Dermatol; 2020 Sep; 59(9):1106-1112. PubMed ID: 32643174
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of treatments for mycosis fungoides and Sézary syndrome: nationwide survey responses.
Gettler SL; Fung MA
Dermatol Online J; 2005 Dec; 11(3):6. PubMed ID: 16409902
[TBL] [Abstract][Full Text] [Related]
15. Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors.
Quadri I; Reneau JC; Hanel W; Chung CG
Front Immunol; 2023; 14():1291259. PubMed ID: 38022633
[TBL] [Abstract][Full Text] [Related]
16. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
[TBL] [Abstract][Full Text] [Related]
17. Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome.
Kawana Y; Suga H; Kamijo H; Miyagaki T; Sugaya M; Sato S
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830466
[TBL] [Abstract][Full Text] [Related]
18. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.
Porcu P; Hudgens S; Horwitz S; Quaglino P; Cowan R; Geskin L; Beylot-Barry M; Floden L; Bagot M; Tsianakas A; Moskowitz A; Huen A; Dreno B; Dalle S; Caballero D; Leoni M; Dale S; Herr F; Duvic M
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):97-105. PubMed ID: 33158772
[TBL] [Abstract][Full Text] [Related]
19. Cost of Treating Cutaneous T-Cell Lymphoma in Spain: Analysis of MICADOS Study Data by Disease Stage.
Navarro Matilla B; Ortiz Romero PL; Pujol Vallverdú RM; Combalia Escudero A; Zapata Paz I; González Barca E; Muniesa Montserrat C; Morillo Andújar M; Pérez Ferriols A; Román Curto C; Fernández de Misa Cabrera R; Hospital Gil M; Marín Niebla A; Rios Rull PJ; de la Cruz Vicente F; Izu Belloso RM; Martín García-Sancho A; Parera Amer ME; Córdoba Mascuñano R; Ramón Quiles MD; Saus Carreres A; Del Campo García R; Machan S; Viguera Ester P; Blanco Garnelo J
Actas Dermosifiliogr; 2024 Feb; 115(2):119-129. PubMed ID: 37689349
[TBL] [Abstract][Full Text] [Related]
20. The impact of gender, age, race/ethnicity, and stage on quality of life in a spectrum of cutaneous lymphomas.
Martinez XU; Chowdhury A; Stiller T; Palmer J; Loscalzo M; Barrios E; Abdulla FR; Zain J; Rosen ST; Querfeld C
Support Care Cancer; 2021 Nov; 29(11):6669-6679. PubMed ID: 33963457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]